Biotechnology Companies in the News Editor’s Note: The home page of the BioNJ Web site provides an up-to-the-minute headline service where readers can access press releases issued by New Jersey-based biotechnology companies. Go to the “New Jersey Biotechnology Company News” section on the BioNJ home page (www.BioNJ.org) to read the latest news. Companies wishing to appear in the BioLines Biotechnology Companies in the News section are encouraged to send their news releases to BioNJ via e-mail at [email protected]. November 4 Merck’s Investigational 9-valent HPV Vaccine, V503, Prevented 97 Percent of Cervical, Vaginal and Vulvar Pre-cancers Caused by Five Additional HPV Types, in Phase III Study http://www.mercknewsroom.com/news-release/research-and-development-news/mercks- investigational-9-valent-hpv-vaccine-v503-prevente Antares Pharma Appoints Dr. Bruce Freundlich as Senior Vice President http://www.businesswire.com/news/home/20131104005132/en/Antares-Pharma-Appoints-Dr.- Bruce-Freundlich-Senior ADMA Biologics Completes Enrollment of Phase III Study for RI-002 http://www.businesswire.com/news/home/20131104005564/en/ADMA-Biologics-Completes- Enrollment-Phase-III-Study Alliance Life Sciences Participates as Event Sponsor at ISPOR 16th Annual European Congress, Presents Examination of Biotech Industry’s Performance on the Stock Market http://www.bioportfolio.com/news/article/1705865/Alliance-Life-Sciences-Participates-as-Event- Sponsor-at-ISPOR-16th-Annual-European.html November 2 BMS Submits First All-Oral, Interferon-Free and Ribavirin-Free Treatment Regimen for Regulatory Review in Japan for Patients with Chronic Hepatitis C Infection http://news.bms.com/press-release/bms-submits-first-all-oral-interferon-free-and-ribavirin-free- treatment-regimen-regula Merck Announces Presentation of Interim Data from Study of Investigational Combination of HCV Therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases (AASLD) Annual Meeting http://www.mercknewsroom.com/news-release/research-and-development-news/merck- announces-presentation-interim-data-study-investiga 1 October 31 Edge Therapeutics Enrolls First Patient in Phase 1/2 NEWTON Study of EG-1962 for Prevention of Delayed Cerebral Ischemia http://finance.yahoo.com/news/edge-therapeutics-enrolls-first-patient-103000583.html Antares Pharma to Host Third Quarter 2013 Operating and Financial Results Conference Call http://finance.yahoo.com/news/antares-pharma-host-third-quarter-110000991.html Protalex Initiates Enrollment of Final Cohort in Phase 1b Trial of PRTX-100 in Active Rheumatoid Arthritis Patients http://www.businesswire.com/news/home/20131031005799/en/Protalex-Initiates-Enrollment- Final-Cohort-Phase-1b electroCore's clinical trial program into non invasive vagus nerve stimulation therapy gathers momentum http://www.businesswire.com/news/home/20131031005886/en/electroCores-clinical-trial- program-invasive-vagus-nerve Soligenix Submits NIAID Contract Proposal for Development of a Thermostable Ricin Vaccine http://www.soligenix.com/news.aspx?titleId=436 October 30 IMS Health Identifies Opportunities for Mobile Healthcare Apps to Drive Patient Engagement, Enhance Delivery of Care http://www.businesswire.com/news/home/20131030005221/en/IMS-Health-Identifies- Opportunities-Mobile-Healthcare-Apps Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress http://newsroom.celgene.com/press-release/corporate/celgene-corporation-webcast-upcoming- investor-conferences-and-medical-congre Dr. Greg Koski, Head of ACRES Global Clinical Research Network, Elected to SAFE- BioPharma Board of Directors http://finance.yahoo.com/news/dr-greg-koski-head-acres-124300194.html Darren Alkins Picked to Head Alvogen Americas http://www.businesswire.com/news/home/20131030005121/en/Darren-Alkins-Picked-Head- Alvogen-Americas Phyxius Pharma in Conjunction with Oxygen Biotherapeutics Announces New Evidence That Levosimendan Can Reduce Mortality in Heart Surgery Patients http://www.businesswire.com/news/home/20131030005494/en/Phyxius-Pharma-Conjunction- Oxygen-Biotherapeutics-Announces-Evidence Agano Solutions and Auditgraph Announce Advisory Board http://www.businesswire.com/news/home/20131030006147/en/Agano-Solutions-Auditgraph- Announce-Advisory-Board 2 STENTYS Self-Apposing Stent Performs Well in New Coronary Indications http://www.businesswire.com/news/home/20131030006059/en/STENTYS-Self-Apposing-Stent- Performs-Coronary-Indications Photocure provides update on Visonac®http://finance.yahoo.com/news/lutonix-six- month-results-presented-201100672.html http://www.photocure.com/Pressmedia/News/Visonac-agreement/ Lutonix Six-Month Results Presented on First IDE Trial for Drug-Coated Balloons http://finance.yahoo.com/news/lutonix-six-month-results-presented-201100672.html The Medicines Company's EUROMAX Trial of Angiox(R) (Bivalirudin) in Heart Attack Meets All Prespecified Endpoints http://ir.themedicinescompany.com/phoenix.zhtml?c=122204&p=irol- newsArticle&ID=1870307&highlight= October 29 RSV Vaccines for the World 2013 Conference Presentation Highlights Data from ADMA Biologics’ Human and Animal Study Experience http://www.businesswire.com/news/home/20131029005742/en/RSV-Vaccines-World-2013- Conference-Presentation-Highlights Vention Medical Acquires Fast Forward Medical http://www.businesswire.com/news/home/20131029005983/en/Vention-Medical-Acquires-Fast- Medical STENTYS Sirolimus-Eluting Stent Demonstrates Faster Arterial Healing Than Conventional Drug-Eluting Stent http://www.businesswire.com/news/home/20131029006580/en/STENTYS-Sirolimus-Eluting- Stent-Demonstrates-Faster-Arterial-Healing Merck Announces Presentation of Interim Data from Phase 1B Study of MK-3475, Investigational anti-PD-1 Immunotherapy, in Previously-Treated Patients with Non-Small Cell Lung Cancer (NSCLC) at 15th World Conference on Lung Cancer http://www.mercknewsroom.com/news-release/research-and-development-news/merck- announces-presentation-interim-data-phase-1b-study- Second Annual Leadership Summit for Interventional Cardiologists Held in San Francisco http://ir.themedicinescompany.com/phoenix.zhtml?c=122204&p=irol- newsArticle&ID=1869687&highlight= October 28 Advaxis Appoints Gregory T. Mayes as Chief Operating Officer http://finance.yahoo.com/news/advaxis-appoints-gregory-t-mayes-120000645.html KCI Completes Acquisition of Systagenix http://finance.yahoo.com/news/kci-completes-acquisition-systagenix-145400492.html NPS Pharmaceuticals to Report Third Quarter 2013 Financial Results http://www.npsp.com/investors-pr?trxml_v=nrd&trxml_nr_id=1869295 3 Soligenix to Host Conference Call and Webcast Discussion on Oral Mucositis http://www.soligenix.com/news.aspx?titleId=435 Promising Phase IIb Data On Clazakizumab In Patients With Moderate-To-Severe Rheumatoid Arthritis To Be Presented At The 2013 Annual Meeting Of The American College Of Rheumatology http://news.bms.com/press-release/financial-news/promising-phase-iib-data-clazakizumab- patients-moderate-severe-rheumato Howie Mandel Challenges People To Learn The Fibs And Facts About Atrial Fibrillation And Its Associated Increased Stroke Risk http://news.bms.com/press-release/partnering-news/howie-mandel-challenges-people-learn- fibs-and-facts-about-atrial-fibri Merck Announces Third-Quarter 2013 Financial Results http://www.mercknewsroom.com/news-release/corporate-news/merck-announces-third-quarter- 2013-financial-results October 25 Epratuzumab’s Mechanism of Action Featured in Blood, Official Journal of The American Society of Hematology http://finance.yahoo.com/news/epratuzumabs-mechanism-action-featured-blood- 123000489.html GE Healthcare Announces FDA Approval of Vizamyl™ (Flutemetamol F18 Injection) for Detection of Beta Amyloid http://www.businesswire.com/news/home/20131025005773/en/GE-Healthcare-Announces- FDA-Approval-Vizamyl%E2%84%A2-Flutemetamol Additional Survival Data on Nivolumab, an Investigational PD-1 Immune Checkpoint Inhibitor, from Lung Cancer Cohort of a Phase 1 Study Presented at 15th World Conference on Lung Cancer http://news.bms.com/press-release/rd-news/additional-survival-data-nivolumab-investigational- pd-1-immune-checkpoint-inhi October 24 Merck Provides Update on Investigational 9-valent HPV Vaccine V503 to U.S. Advisory Committee on Immunization Practices http://www.mercknewsroom.com/news-release/research-and-development-news/merck- provides-update-investigational-9-valent-hpv-vaccin Celgene Reports Strong Third Quarter 2013 Operating and Financial Results http://finance.yahoo.com/news/celgene-reports-strong-third-quarter-113100186.html NPS Pharmaceuticals Submits Biologic License Application to the U.S. Food and Drug Administration for Natpara® in Hypoparathyroidism http://www.npsp.com/investors-pr?trxml_v=nrd&trxml_nr_id=1868017 Bristol-Myers Squibb Prices $1.5 Billion of Senior Notes http://news.bms.com/press-release/financial-news/bristol-myers-squibb-prices-15-billion-senior- notes 4 October 23 Results for the third quarter and the first nine months 2013 http://www.photocure.com/Pressmedia/News/2Q13-Report-/ Bristol-Myers Squibb Reports Third Quarter 2013 Financial Results http://news.bms.com/press-release/financial-news/bristol-myers-squibb-reports-third-quarter- 2013-financial-results ZOSTAVAX® (Zoster Vaccine Live) Awarded Prix Galien USA 2013 Best Biotechnology Product http://www.mercknewsroom.com/news-release/prescription-medicine-news/zostavax-zoster- vaccine-live-awarded-prix-galien-usa-2013-be The Merck Manual Go-To Home Guide for Symptoms Helps Patients Assess When